MedTrace Logo

Organoids-on-a-chip for Colorectal Cancer and in Vitro Screening of Chemotherapeutic Drugs

NCT04996355 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2021-08-18

No results posted yet for this study

Summary

The individualized treatment of tumors has always been an urgent problem in clinical practice. Organoids-on-a-chip can reflect the heterogeneity of tumors and is a good model for in vitro anticancer drug screening. In this study, surgical specimens of patients with advanced colorectal cancer will be collected for organoid culture and organoids-on-a- chip. Use organoids-on-a-chip to screen tumor chemotherapy drugs, compare the results of patients' actual medication regimens, and study the guiding role of organoids in the formulation of precise tumor treatment plans. The investigators will compare the response of organoids to drugs in vitro with the patient's response to actual chemotherapy and targeted drugs and explore the feasibility and accuracy of organoids-on-a-chip based drug screening for advanced colorectal cancer. The project will establish a screening platform for chemotherapeutic drugs and targeted drugs based on colorectal cancer organoids to quickly and accurately formulate personalized treatment plans for clinical patients.

Conditions

  • Colorectal Neoplasms
  • Organoids

Interventions

OTHER

comprehensive treatment after MDT discussion

The comprehensive treatment plan was determined through MDT discussion, which was completed by the Department of Gastrointestinal Surgery, Peking University People's Hospital. The following regimens will be tested with organoids-on-a-chip： 1. 5-FU 2. Oxaliplatin 3. Irinotecan 4. 5-FU+ Oxaliplatin 5. 5-FU+ Irinotecan 6. 5-FU+ Oxaliplatin+ Irinotecan 7. 5-FU+Cetuximab 8. Cetuximab 9. Regorafenib

Sponsors & Collaborators

  • Peking University

    collaborator OTHER

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Yingjiang Ye, PHD&MD · Peking University People's Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-31
Primary Completion
2022-05-30
Completion
2024-05-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04996355 on ClinicalTrials.gov